Close Menu

NEW YORK (GenomeWeb) – Asuragen today announced its Quantidex BCR-ABL IS CMR Kit has received the CE-IVD mark. 

The firm is launching the kit for monitoring BCR-ABL1 transcript levels in chronic myeloid leukemia patients this week. According to Asuragen, the product improves upon other tests by attaining a sensitivity of MR4.7 while it allows direct reporting on the International Scale. Additionally, the assay enables detection of complete molecular response. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.

Sponsored by

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.